{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:22:54Z","timestamp":1787016174055,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T00:00:00Z","timestamp":1478044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006432","name":"Terumo BCT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Middle East respiratory syndrome coronavirus (MERS\u2010CoV) has been identified as a potential threat to the safety of blood products. The Mirasol Pathogen Reduction Technology System uses riboflavin and ultraviolet (UV) light to render blood\u2010borne pathogens noninfectious while maintaining blood product quality. Here, we report on the efficacy of riboflavin and UV light against MERS\u2010CoV when tested in human plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN AND METHODS<\/jats:title>\n                    <jats:p>MERS\u2010CoV (EMC strain) was used to inoculate plasma units that then underwent treatment with riboflavin and UV light. The infectious titers of MERS\u2010CoV in the samples before and after treatment were determined by plaque assay on Vero cells. The treatments were initially performed in triplicate using pooled plasma (n\u2009=\u20093) and then repeated using individual plasma units (n\u2009=\u20096).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In both studies, riboflavin and UV light reduced the infectious titer of MERS\u2010CoV below the limit of detection. The mean log reductions in the viral titers were \u22654.07 and \u22654.42 for the pooled and individual donor plasma, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Riboflavin and UV light effectively reduced the titer of MERS\u2010CoV in human plasma products to below the limit of detection, suggesting that the treatment process may reduce the risk of transfusion transmission of MERS\u2010CoV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.13860","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T07:57:46Z","timestamp":1478073466000},"page":"2948-2952","source":"Crossref","is-referenced-by-count":110,"title":["Inactivation of\n                    <scp>M<\/scp>\n                    iddle\n                    <scp>E<\/scp>\n                    ast respiratory syndrome coronavirus (\n                    <scp>MERS\u2010C<\/scp>\n                    o\n                    <scp>V<\/scp>\n                    ) in plasma products using a riboflavin\u2010based and ultraviolet light\u2010based photochemical treatment"],"prefix":"10.1111","volume":"56","author":[{"given":"Shawn D.","family":"Keil","sequence":"first","affiliation":[{"name":"Terumo BCT Lakewood Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bowen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Colorado State University Fort Collins Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Marschner","sequence":"additional","affiliation":[{"name":"Terumo BCT Lakewood Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12070"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0450-0"},{"key":"e_1_2_9_4_1","unstructured":"Kingdom of Saudi Arabia Ministry of Health. MERS\u2010CoV Statistics. [cited 2015 Sep 27] Available from:http:\/\/www.moh.gov.sa\/en\/CCC\/PressReleases\/Pages\/default.aspx."},{"key":"e_1_2_9_5_1","unstructured":"World Health Organization.Middle East respiratory syndrome coronavirus (MERS\u2010CoV); MERS\u2010CoV in Republic of Korea at a glance. World Health Organization. [cited 2015 Sep 28] Available from:http:\/\/www.wpro.who.int\/outbreaks_emergencies\/wpro_coronavirus\/en\/."},{"key":"e_1_2_9_6_1","first-page":"61","article-title":"Centers for Disease Control and Prevention. Update on the epidemiology of Middle East respiratory syndrome coronavirus (MERS\u2010CoV) infection, and guidance for the public, clinicians, and public health authorities\u2014January 2015","volume":"64","author":"Rha B","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030747"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2003.09.011"},{"key":"e_1_2_9_9_1","unstructured":"Middle East respiratory syndrome coronavirus. American Association of Blood Banks. [cited 2015 Sep 27] Available from:http:\/\/www.aabb.org\/tm\/eid\/Documents\/middle-east-respiratory-syndrome-coronavirus.pdf."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13030"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12079"},{"key":"e_1_2_9_12_1","first-page":"e52820","article-title":"Treatment of platelet products with riboflavin and UV light: effectiveness against high titer bacterial contamination","volume":"102","author":"Keil SD","year":"2015","journal-title":"J Vis Exp"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03355.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2013.05.035"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02272.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02517.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2012.141280"},{"key":"e_1_2_9_18_1","volume-title":"Guide to the preparation, use, and quality assurance of blood components","author":"European Directorate for the Quality of Medicines and Healthcare","year":"2013"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/cid\/civ951","article-title":"Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection","volume":"62","author":"Corman VM","year":"2016","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.07.005"},{"key":"e_1_2_9_21_1","first-page":"1335","article-title":"HIV transmission through transfusion\u2014Missouri and Colorado, 2008","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2011.07.006"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tree.2005.02.009"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.13860","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.13860","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.13860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:21:39Z","timestamp":1749669699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.13860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,2]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/trf.13860"],"URL":"https:\/\/doi.org\/10.1111\/trf.13860","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,2]]}}}